ROBOSENSE
19.5.2023 13:01:28 CEST | Business Wire | Press release
RoboSense, a world-leading provider of smart LiDAR sensor systems, today announced it is now connected to the NVIDIA Omniverse ecosystem, using the development platform based on Universal Scene Description (USD) to accelerate the development, testing, and validation of its sensor technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005153/en/
RoboSense Joins NVIDIA Omniverse Ecosystem RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. (Graphic: Business Wire)
RoboSense's second-generation smart solid-state LiDAR model is integrated into NVIDIA DRIVE Sim, built on Omniverse, enabling physically based, high-fidelity sensor simulation. With this integration, autonomous vehicle developers can directly access state-of-the-art LiDAR for development and testing. (Video: RoboSense LiDAR Model in NVIDIA DRIVE Sim)
DRIVE Sim is a reference application built on NVIDIA Omniverse, the connecting fabric between software ecosystems. It combines NVIDIA’s core technologies to deliver digital twin environments for developing and testing autonomous driving systems. With DRIVE Sim, developers can perform diverse and repeatable testing scenarios at a large scale, accelerating development and reducing cost.
As part of the Omniverse ecosystem, RoboSense will use the simulation platform to test and validate its new LiDAR systems - as well as provide ADAS developers access to highly accurate simulation models.
RoboSense's M-Series LiDAR is the world's first second-generation smart solid-state LiDAR to achieve mass production for automotive applications. It is currently the LiDAR with the most designated partnerships worldwide and has been implemented in a variety of vehicle models including the GAC Aion LX Plus, GAC Aion Hyper GT, SAIC IM LS7, SAIC IM L7, Lotus Eletre, XPeng G9, XPeng P7i, Great Wall WEY Mocha DHT-PHEV, Great Wall Motor WEY DHT-PHEV, and Chery Exeed STERRA ES, STERRA ET.
The M-Series LiDAR features a revolutionary two-dimensional MEMS scanning architecture, with unique “GAZE” function that can dynamically switch scanning modes and change scanning patterns based on the scenario, improving vehicle perception in complex environments. Based on RoboSense's leading patented technology, the M-Series LiDAR delivers point-cloud with outstanding quality, helping to address corner cases in autonomous driving perception.
By joining the NVIDIA Omniverse ecosystem, RoboSense enables developers to create complex road environments with high physical accuracy using its LiDAR model on the DRIVE Sim platform. The M series LiDAR model offers the flexibility to simulate its performance in beam control, custom scan patterns, and resolutions, which can then be used to generate synthetic datasets for training and validation of autonomous driving solutions.
Mark Qiu, co-founder and executive president of RoboSense, said, “The global automotive industry is undergoing a massive transformation, with ADAS and LiDAR markets continuing to gain traction. Leveraging the NVIDIA Omniverse ecosystem, RoboSense LiDAR technology and industry experience can be applied in a wider field, providing strong support for the development and verification of autonomous vehicles. RoboSense will work with NVIDIA to fully leverage the advantages of LiDAR technology, continuously improve the perception capabilities of autonomous vehicles, and achieve more efficient, safer, and smarter autonomous driving applications. We are committed to promoting the development of the global automotive and autonomous driving industries.”
Zvi Greenstein, a general manager at NVIDIA, said, “NVIDIA Omniverse is an open platform that includes leading LiDAR models from manufacturers worldwide. RoboSense's outstanding technical strength and customer base help strengthen our ecosystem and will accelerate the development and validation of autonomous vehicles while bringing more flexibility to developers.”
About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom